Global Information
회사소개 | 문의 | 비교리스트

세계의 화학요법 시장(2019-2023년)

Global Chemotherapy Treatment Market 2019-2023

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2019년 05월 상품 코드 843044
페이지 정보 영문 136 Pages
가격
US $ 2,500 ₩ 2,971,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,565,000 PDF (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,753,000 PDF (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,942,000 PDF (Global License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 화학요법 시장(2019-2023년) Global Chemotherapy Treatment Market 2019-2023
발행일 : 2019년 05월 페이지 정보 : 영문 136 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 화학요법 시장은 암 유병률 상승과 화학요법제 수요 증가, 최근의 화학요법 신규 승인 등에 의해 성장이 촉진되고 있습니다. 시장은 2023년까지 3%의 CAGR로 성장할 것으로 예측됩니다.

세계의 화학요법(Chemotherapy Treatment) 시장을 조사했으며, 시장 개요, 의약품 클래스·지역별 시장 규모 추정과 예측, 시장 성장 촉진요인 및 과제 분석, 시장 동향, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 주요 요약

제2장 보고서 범위

제3장 시장 상황

  • 시장 생태계
  • 시장 특징
  • 시장 세분화 분석

제4장 시장 규모

  • 시장 정의
  • 시장 규모
  • 시장 규모 추정과 예측

제5장 Five Forces 분석

  • 구매자의 협상력
  • 공급 기업의 협상력
  • 신규 참여업체의 위협
  • 대체품의 위협
  • 경쟁 기업간 경쟁 관계
  • 시장 현황

제6장 시장 세분화 : 의약품 클래스별

  • 시장 구분 : 의약품 클래스별
  • 시장 비교 : 의약품 클래스별
  • 대사길항제
  • 식물 유도체
  • 세포독성 항생물질
  • 알킬화제
  • 기타
  • 시장 기회 : 의약품 클래스별

제7장 고객 상황

제8장 지역 상황

  • 시장 구분 : 지역별
  • 시장 비교 : 지역별
  • 북미
  • 유럽
  • 아시아
  • 기타 지역
  • 주요 국가
  • 시장 기회

제9장 의사결정 체계

제10장 성장 촉진요인과 과제

  • 시장 성장 촉진요인
  • 시장 과제

제11장 시장 동향

제12장 벤더 상황

  • 개요
  • 창조적 파괴 상황

제13장 벤더 분석

  • 대상 벤더
  • 벤더 분류
  • 벤더의 시장 포지셔닝
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.

제14장 부록

  • 조사 방법
  • 약어 리스트
  • 벤더의 시장 포지셔닝 정의

제15장 TechNavio 소개

KSM 19.05.23

About this market

The recent approvals of chemotherapeutics to treat cancer is one of the key factors expected to trigger the chemotherapy treatment market during the forecast period. With the rising prevalence of cancer, the demand for chemotherapeutics agents is increasing. The market has witnessed recent approvals of chemotherapeutics agents such as TECENTRIQ by regulatory authorities in different regions. TECENTRIQ in combination with carboplatin and etoposide is being used for first-line treatment of adult patients with extensive-stage, small-cell lung cancer. This will boost the chemotherapy treatment market growth during the forecast period. Technavio's analysts have predicted that the chemotherapy treatment market will register a CAGR of nearly 3% by 2023.

Market Overview

Availability of drugs to treat the side-effects of chemotherapy

The drugs used in chemotherapy for cancer treatment have several side-effects such as vomiting and nausea, hypersensitivity reactions, and neutropenia. Hence, the availability of drugs to treat these side-effects will drive the growth of the market during the forecast period.

Emerging targeted therapies

The market has witnessed the development and approval of targeted therapies to treat different cancers, such as prostate cancer, lung and bronchus cancer, and thyroid cancer. This may pose a challenge to the global chemotherapy treatment market.

For the detailed list of factors that will drive and challenge the growth of the chemotherapy treatment market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately concentrated with the presence of a few market players. Several vendors in the market are focusing on the development of combination therapies with chemotherapy drugs along with targeted therapies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY DRUG CLASS

  • Market segmentation by drug class
  • Comparison by drug class
  • Antimetabolites - Market size and forecast 2018-2023
  • Plant derivatives - Market size and forecast 2018-2023
  • Cytotoxic antibiotics - Market size and forecast 2018-2023
  • Alkylating agents - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by drug class

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Market trends

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Segments of global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Combination therapy approvals
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Drug class - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by drug class
  • Exhibit 20: Antimetabolites - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Antimetabolites - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Plant derivatives - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Plant derivatives - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Cytotoxic antibiotics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Cytotoxic antibiotics - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Alkylating agents - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Alkylating agents - Year-over-year growth 2019-2023 (%)
  • Exhibit 28: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Market opportunity by drug class
  • Exhibit 31: Customer landscape
  • Exhibit 32: Market share by geography 2018-2023 (%)
  • Exhibit 33: Geographic comparison
  • Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Approvals of chemotherapeutics
  • Exhibit 45: Side-effects of chemotherapy drugs
  • Exhibit 46: Impact of drivers and challenges
  • Exhibit 47: Combination therapies under late-stage clinical trials
  • Exhibit 48: Repurposed chemotherapy agents
  • Exhibit 49: Antibody drug conjugates undergoing clinical trials
  • Exhibit 50: Vendor landscape
  • Exhibit 51: Landscape disruption
  • Exhibit 52: Vendors covered
  • Exhibit 53: Vendor classification
  • Exhibit 54: Market positioning of vendors
  • Exhibit 55: Bristol-Myers Squibb Co. - Vendor overview
  • Exhibit 56: Bristol-Myers Squibb Co. - Business segments
  • Exhibit 57: Bristol-Myers Squibb Co. - Organizational developments
  • Exhibit 58: Bristol-Myers Squibb Co. - Geographic focus
  • Exhibit 59: Bristol-Myers Squibb Co. - Key offerings
  • Exhibit 60: Eli Lilly and Co. - Vendor overview
  • Exhibit 61: Eli Lilly and Co. - Business segments
  • Exhibit 62: Eli Lilly and Co. - Organizational developments
  • Exhibit 63: Eli Lilly and Co. - Geographic focus
  • Exhibit 64: Eli Lilly and Co. - Segment focus
  • Exhibit 65: Eli Lilly and Co. - Key offerings
  • Exhibit 66: Johnson & Johnson Services Inc. - Vendor overview
  • Exhibit 67: Johnson & Johnson Services Inc. - Business segments
  • Exhibit 68: Johnson & Johnson Services Inc. - Organizational developments
  • Exhibit 69: Johnson & Johnson Services Inc. - Geographic focus
  • Exhibit 70: Johnson & Johnson Services Inc. - Segment focus
  • Exhibit 71: Johnson & Johnson Services Inc. - Key offerings
  • Exhibit 72: Novartis AG - Vendor overview
  • Exhibit 73: Novartis AG - Business segments
  • Exhibit 74: Novartis AG - Organizational developments
  • Exhibit 75: Novartis AG - Geographic focus
  • Exhibit 76: Novartis AG - Segment focus
  • Exhibit 77: Novartis AG - Key offerings
  • Exhibit 78: Pfizer Inc. - Vendor overview
  • Exhibit 79: Pfizer Inc. - Business segments
  • Exhibit 80: Pfizer Inc. - Organizational developments
  • Exhibit 81: Pfizer Inc. - Geographic focus
  • Exhibit 82: Pfizer Inc. - Segment focus
  • Exhibit 83: Pfizer Inc. - Key offerings
  • Exhibit 84: Validation techniques employed for market sizing
  • Exhibit 85: Definition of market positioning of vendors
Back to Top
전화 문의
F A Q